Testing two drugs together for triple negative breast cancer that spread to the brain
Official title: A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests a pair of drugs in people whose breast cancer has reached the brain.
Read our full plain-language summary
What the trial team says
This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment for brain metastases from triple-negative advanced breast cancer cases.
Key facts
- Registry number
- NCT06598046
- Stage of testing
- Phase 2
- Conditions studied
- Metastatic Breast Cancer
Where it is running
This trial lists 1 site.
-
Henan
- Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University (Zhengzhou)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.